Wadt Hansen, K. et al. (2021) Association of fatal myocardial infarction with past level of physical activity: a pooled analysis of cohort studies. *European Journal of Preventive Cardiology*, 28(14), pp. 1590-1598.

(doi: [10.1093/eurjpc/zwaa146](https://doi.org/10.1093/eurjpc/zwaa146))

This is the Author Accepted Manuscript.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<https://eprints.gla.ac.uk/243862/>

Deposited on: 15 June 2021

Association of Fatal Myocardial Infarction with Past Level of Physical Activity

A Pooled Analysis of Cohort Studies

AUTHORS

Kim Wadt Hansen, MD PhD¹; Nina Peytz, MD²; Anneke Blokstra, MSc³; Stig E Bojesen, MD PhD DMSc²; Carlos Celis-Morales, PhD⁴; Christina Chrysohoou, MD PhD⁵; Els Clays, PhD⁶; Dirk De Bacquer, PhD⁵; Søren Galatius, MD DMSc¹; Stuart R Gray, BSc PhD⁴; Frederick Ho, BSc PhD⁴; Maryam Kavousi, MD PhD FESC⁷; Chantal M Koolhaas, MSc⁷; Matina Kouvari, MSc⁸; Maja-Lisa Løchen, MD PhD⁹; Pedro Marques-Vidal, MD, PhD¹⁰; Merete Osler¹¹; Demosthenes Panagiotakos, DMSc FACE FRSPH⁸; Jill P Pell, MD FRSE FMedSci¹²; Gerhard Sulo, MD PhD¹³; Grethe S Tell, MPH PhD¹⁴; Vassilios Vassiliou, MA MBBS PhD FRCP FACC FESC¹⁵; W M Monique Verschuren, PhD³; Eva Prescott, MD DMSc¹.

AFFILIATIONS

¹ Department of Cardiology, Bispebjerg Frederiksberg University Hospital, Copenhagen, Denmark.

² Department of Clinical Medicine, Herlev Gentofte University Hospital, Copenhagen, Denmark.

³ Department of Life Course and Health, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

⁴ Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom.

⁵ First Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece.

⁶ Department of Public Health and Primary Care, University Ghent, Ghent, Belgium.

⁷ Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

1 ⁸ Department of Nutrition – Dietetics, School of Health Science and Education, Harokopio University of Athens,
2 Athens, Greece.

3 ⁹ Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.

4 ¹⁰ Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne,
5 Lausanne, Switzerland.

6 ¹¹ Section for Population-based Epidemiology, Center for Clinical Research and Prevention, Bispebjerg
7 Frederiksberg University Hospital, Copenhagen, Denmark.

8 ¹² Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

9 ¹³ Norwegian Institute of Public Health, Bergen, Norway.

10 ¹⁴ Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

11 ¹⁵ Norwich Medical School, University of East Anglia, Norwich and Imperial College London, United Kingdom.

12

13 **PREVIOUS PRESENTATIONS**

14 Preliminary results from this paper was presented at the 2019 ESC Congress in Paris, France as a Late Breaking
15 Session, Preventive Cardiology.

16

17 **WORD COUNT**

18 3934

19

20

1 **CORRESPONDENCE TO:**

2 Kim Wadt Hansen, MD PhD

3 Department of Cardiology

4 Bispebjerg Frederiksberg University Hospital

5 Bispebjerg Bakke 23, Building 67, 1st floor

6 DK-2400 Copenhagen NV

7 Phone: +45 5080 2117

8 Fax: +45 3531 2004

9 Email: kim.wadt.hansen@regionh.dk

10

11

12

13

14

15

16

17

18

19

1 **ABBREVIATIONS**

BMI	-	Body-mass index
CI	-	Confidence interval
CVD	-	Cardiovascular disease
MET	-	Metabolic equivalent
MI	-	Myocardial infarction
OR	-	Odds ratio
PA	-	Physical activity
SE	-	Standard error

2

3

4

5

6

7

8

1 Abstract

2 Aims

3 To assess the association between past level of physical activity (PA) and risk for death during the acute phase
4 of a myocardial infarction (MI) in a pooled analysis of cohort studies.

5 Materials

6 European cohorts including participants with baseline assessment of PA, conventional cardiovascular risk
7 factors, and available follow-up on MI and death were eligible. Patients with an incident MI were included.
8 Leisure-time PA was grouped as sedentary (<7 MET-hrs), low (7-16 MET-hrs), moderate (16.1-32 MET-hrs), or
9 high (>32 MET-hrs) based on calculated net weekly energy expenditure. The main outcome measures were
10 instant and 28-day case-fatality of MI. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were
11 calculated using multivariate random-effects models. Adjustments for age, sex, cardiovascular risk factors,
12 alcohol consumption, and socioeconomic status were made.

13 Results

14 From ten cohorts including a total of 1 495 254 participants, 28 140 patients with an incident MI comprised the
15 study population. A total of 4976 (17.7%) died within 28 days – of these 3101 (62.3%) were classified as instant
16 fatal MI. Compared with sedentary individuals, those with a higher level of PA had lower adjusted odds of
17 instant fatal MI: low PA (OR, 0.79 [95% CI, 0.60-1.04]), moderate PA (0.67 [0.51-0.89]), and high PA (0.55 [0.40-
18 0.76]). Similar results were found for 28-day fatal MI: low PA (0.85 [0.71-1.03]), moderate PA (0.64 [0.51-0.80]),
19 and high PA (0.72 [0.51-1.00]). A low-to-moderate degree of heterogeneity was detected in the analysis of
20 instant fatal MI ($I^2 = 47.3\%$), but not in that of 28-day fatal MI ($I^2 = 0.0\%$).

1 **Conclusion**

2 A moderate-to-high level of PA was associated with a lower risk of instant and 28-day death in relation to a MI.

3 **Keywords**

4 Pooled analysis; myocardial infarction; cohort studies; physical activity; mortality.

5

6

7

8

9

10

11

12

13

14

15

16

17

1 Introduction

2 Ischemic heart disease (IHD) is the leading cause of death worldwide (1,2). Primary prevention of IHD thus
3 constitutes a major public health priority. Regular physical activity (PA) has been shown to prevent the
4 development and progression of cardiovascular disease (3–5) and reduce all-cause mortality in a dose-
5 response-like manner in healthy populations (6–9). The cardioprotective effects of PA have earned it a central
6 role in the 2016 European guidelines on cardiovascular disease prevention in clinical practice (10). Although the
7 biological mechanisms by which PA exerts its cardioprotective effects are poorly understood, the concept of
8 exercise-induced ischemic preconditioning plays a central role in our current understanding (11,12). Preceding
9 repeated ischemia through exercise may stimulate the release of chemical substances and formation of
10 collaterals increasing blood flow, thus reducing ischemic injury in case of a myocardial infarction (MI) (13,14).
11 Experimental animal models have demonstrated reduced infarct sizes associated with exercise (15–18).
12 Accordingly, less myocardial stunning, less ischemia-induced arrhythmias, improved left ventricular function,
13 and improved survival after a cardiac arrest have been documented in patients hospitalized with MI who
14 experience pre-infarction angina; an equivalent of ischemic preconditioning (19). Despite this strong biological
15 basis for a cardioprotective effect of PA, prospective studies on the relation between PA and risk for death
16 during the acute phase of a MI are scarce (20–22).

17 We undertook a pooled analysis of prospective cohorts to quantitatively assess the association between PA
18 and subsequent risk for death during the acute phase of a MI.

1 Methods

2 Design, study selection and participants

3 The study was designed as a collaborative pooled analysis of cohort studies identified within the Population
4 Science and Public Health nucleus under the European Association of Preventive Cardiology. Methods of the
5 analysis and inclusion criteria were specified in advance and documented in a protocol and a statistical report
6 and analysis plan. European observational cohorts including healthy participants with baseline assessment of
7 PA, conventional cardiovascular risk factors and subsequent follow-up on MI and death (including cause of
8 death) were considered eligible.

9 Participants who experienced a MI during follow-up were eligible for analysis. Exclusion criteria were a history
10 of MI prior to baseline assessment or missing data on physical activity or survival status. The final study
11 populations included participants with an incident MI and available follow-up on both in- and out-of-hospital
12 deaths.

13 All studies fulfilling eligibility criteria, as assessed by a standardized questionnaire, received a joint statistical
14 report and analysis plan specifying variables of interest, data preparation and statistical analyses to be
15 completed locally.

16 Standardisation of physical activity level

17 The exposure variable of interest was level of leisure-time PA at baseline assessment upon entering a cohort.
18 As the studies included in this pooled analysis measured PA differently (e.g. type of activity, metabolic
19 equivalents [MET]), we standardised and grouped level of PA into four categories based on total weekly energy
20 expenditure (MET-hours per week): sedentary (<7 MET-hrs per week), low (7-16 MET-hrs per week), moderate
21 (16.1-32 MET-hrs per week), and high (>32 MET-hrs per week). This classification was based on applying the

conversion rules from the validated International Physical Activity Questionnaire (IPAQ) based on the updated Compendium of Physical Activity (<https://sites.google.com/site/compendiumofphysicalactivities/>) to the four categories of leisure-time PA used in the Copenhagen City Heart Study questionnaire (21,23). Our cut-off values generally agreed well with those stated in current European guidelines (10). The calculations are shown in the Supplementary Material (Appendix Text).

Main outcome measures and follow-up

The main outcome measure was fatal MI occurring within 28 days of the index event, i.e. case-fatality of MI. Fatal MI was classified as instant if a) date of death coincided with date of MI hospitalization, or b) in the case of out-of-hospital death the cause was registered as MI (ICD-10 code: I21x or I22). Patients who survived the day of index event, but subsequently died within 28 days with MI as the registered cause of death were classified as 28-day fatal MI (24).

Statistical analysis

Cohort level analysis

Each cohort identified all patients suffering a MI event after baseline assessment during follow-up (Appendix Figure 2). The covariates of age, sex, diabetes mellitus, arterial hypertension, family history of CVD, smoking, BMI, total blood cholesterol level, systolic and diastolic blood pressure, alcohol consumption and socioeconomic status were considered potential confounders in the analyses. Aggregated baseline data, numbers of patients and events, and adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were provided for pooled analyses. We used ORs, calculated by logistic regressions with/without adjustments for aforementioned confounders, as our main measure to assess the relation between PA level and fatal MI. For each study we converted these values using their natural logarithms. Standard errors (SEs) and variance were calculated from these logarithmic numbers and their corresponding 95% CIs. Our random-

1 effects pooled analyses of the studies were based on these within-study comparisons, thereby avoiding biases
2 caused by methodological differences between studies.

3 Pooled analysis

4 Using the group with the lowest weekly net energy expenditure (sedentary) as reference, we estimated the
5 pooled ORs and 95% CIs of fatal MI for the low, moderate, and high categories using both fixed- and random-
6 effects multivariate models. Since the use of a common reference group for all three comparisons within each
7 study is likely to result in correlated effect estimates, we included a variance-covariance matrix in each model
8 as described by Gleser et al. (25) to account for this dependency. We calculated the quantity I^2 using the
9 method suggested by Viechtbauer et al. (26,27) to describe the degree of heterogeneity with values of 25%,
10 50%, and 75% considered low, moderate, and high, respectively.

11 The risk of bias across studies was assessed by plotting the effect by the inverse of its standard error for each
12 study in a funnel plot which was assessed visually and using Egger's regression test. Due to the complexity of
13 our data comparison-adjusted funnel plots were generated using a network meta-analytical approach to our
14 patient and event counts; thus, these results were not adjusted for the listed covariates. Estimates from the
15 network meta-analysis are presented in the Supplementary materials (Appendix Table 3).

16 To examine the source of heterogeneity, sensitivity analyses were performed according to selected patient
17 characteristics; specifically, pre-specified subgroups of time from baseline assessment to incident MI (<5 years
18 vs. ≥5 years after baseline assessment of PA), age at time of MI (<65 years vs. ≥65 years), sex (male vs. female),
19 body-mass index (<30 kg/m² vs. ≥30 kg/m²), diabetes mellitus (yes vs. no), and arterial hypertension (yes vs.
20 no).

21 A post-hoc sensitivity analysis was conducted to assess the influence of European region (Scandinavia vs. other
22 European), first year of recruitment (before 1990 vs. between 1990 and 2000 vs. after 2000), and identified

1 data uncertainties, i.e. cohorts with no reported data on prior heart failure (yes vs. no), variation in the
2 distribution of patients according to PA group (<40% vs. ≥40% in high PA group) and the observation of a
3 relatively low prevalence of instant fatal MI in some cohorts (<10% vs. ≥10%) which may suggest
4 underreporting of out-of-hospital death.

5 All analyses were conducted in statistical software R, version 3.4.1 (28). The pooled analysis was performed
6 using the *metafor* package (27) and the *netmeta* package (29).

7 Results

8 A total of 17 European observational cohort studies were invited to participate – three did not respond, three
9 did not fulfil all eligibility criteria, and one study did not have enough data, leaving 10 studies for further
10 analysis (Figure 1). Of the ten cohorts included in the pooled analysis, three were from Denmark (23,30–32),
11 two from the Netherlands (33,34), one from Norway (35), one from Belgium (36), one from Greece (37), and
12 two from the United Kingdom (38). Appendix Table 1 summarises selected characteristics of each cohort study.

13 From a total of 1 495 254 participants, 28 140 individuals subsequently developed an incident MI during follow-
14 up and constituted the study population (Appendix Figure 2). Of the 4976 fatal MIs within 28 days,
15 approximately two-thirds (3101 deaths) were classified as instant fatal MI. Table 2.1 shows the clinical
16 characteristics at baseline assessment of the 28 140 patients who developed an MI. Overall, the distribution of
17 age, sex and cardiovascular risk factors demonstrated significant variation across studies. After weighted
18 pooling of baseline characteristics by level of PA, the sedentary group had the highest prevalence of males,
19 diabetes mellitus and arterial hypertension with a graded decrease across increasingly higher levels of PA
20 (Appendix Table 2). Notably, the distribution of patients according to PA category displayed significant variation
21 across cohorts, i.e. sedentary [range: 1.0% to 61.6%], low PA [range: 3.1% to 54.5%], moderate PA [range: 6.8%
22 to 36.4%], and high PA [range: 0% to 89.1%].

Figures 2 and 3 summarize unadjusted ORs for instant and 28-day fatal MI for the individual studies along with pooled unadjusted and adjusted ORs. Overall, a higher level of PA was associated with lower risk of instant and 28-day fatal MI, seemingly in a dose-response-like manner. Compared with individuals who were sedentary, the pooled fully adjusted ORs for instant fatal MI were 0.79 (95% CI, 0.60-1.04) for those who pursued low PA, 0.67 (CI, 0.51-0.89) for moderate PA, and 0.55 (CI, 0.40-0.76) for high PA. Estimates for the same comparisons for 28-day fatal MI were 0.85 (CI, 0.71-1.03) for low PA, 0.64 (CI, 0.51-0.80) for moderate PA, and 0.72 (CI, 0.51-1.00) for high PA. Heterogeneity was low-to-moderate in the analyses of instant fatal MI, while no evidence of heterogeneity was detected in the analyses of 28-day fatal MI.

Compared with sedentary individuals, those with higher levels of PA had a lower risk of fatal MI, irrespective of time from baseline assessment to MI, age, sex, a history of diabetes mellitus, or a history of arterial hypertension (Table 2). In individuals with a BMI ≥ 30 kg/m² the lower risk of 28-day fatal MI observed across other subgroups was seemingly attenuated with higher level of PA, although tests for subgroup interactions did not reach statistical significance (28-day fatal MI [Chi² = 3.94; df = 2; *P* = 0.14]). Estimates were consistent across all five subgroups in the post-hoc sensitivity analysis (Appendix Table 7).

Estimates from our unadjusted fixed- and random-effects multivariate models (Appendix Table 3) were consistent with those obtained using a network meta-analysis approach (Appendix Table 4). The funnel plots based on estimates from the network meta-analysis did suggest a slight asymmetry for 28-day fatal MI, i.e. smaller studies demonstrating lower odds in the exposure groups were underrepresented in the analysis (Appendix Figure 1). However, Egger's regression test indicated no significant asymmetry of the funnel plots for instant fatal MI (*p*=0.715) and 28-day fatal MI (*p*= 0.495), respectively.

1 Discussion

2 Key findings

3 This pooled analysis has quantitatively assessed the relation between leisure-time PA and risk of death during the
4 acute phase of a MI. The main finding is that increasing levels of PA were associated with a lower risk of instant
5 and 28-day fatal MI in a seemingly dose-response-like manner. Compared with individuals who were
6 sedentary, those participating in moderate- and high-level PA had a 33% and 45% lower risk of instant fatal MI,
7 while 1-day survivors had a 36% and 28% lower risk of 28-day fatal MI, respectively. Our findings support the
8 hypothesis that PA has cardioprotective capabilities.

9 Interpretation

10 The relationship between PA and all-cause mortality has been extensively investigated in the epidemiological
11 literature and a clear biological gradient has been demonstrated; i.e. an increased PA level confers a lower risk
12 for all-cause death in healthy adults (6–9). Similar findings have been reported for cardiovascular disease and
13 death (4,5). To the best of our knowledge only four smaller, observational studies - two of them included in the
14 current pooled analysis, have addressed the question of how PA levels may modulate the course of a MI in
15 human subjects (20,21,39). Combined these studies suggested that higher PA levels prior to a MI were
16 inversely associated with cardiac biomarker levels, in-hospital death and subsequent cardiovascular events
17 within 1 months of discharge. However, two of these studies did not report out-of-hospital deaths which is
18 likely to result in underestimation of the association (20,39). Our pooled analysis is consistent with these
19 reported findings, but further extends them by demonstrating that the survival-benefit is immediate,
20 consistent across clinically relevant subgroups, and preserved at 28 days in patients surviving the first 24 hours
21 of a MI.

Our subgroup analysis showed consistency of the association of fatal MI with PA. The strength of association seemed higher in men and those ≥ 65 years, but tests for interaction did not reach statistical significance and heterogeneity was found to be high in these subgroups. We also observed an inverse relationship in patients with a BMI ≥ 30 kg/m² with an attenuation of the risk estimate across higher levels of PA. Prior studies have shown that factors such as existing cardiorespiratory fitness or the presence of pre-infarction angina may play an important role in these subgroups (39–41); factors unaccounted for in our analysis. The limited number of cohorts and events indicate that the results of our subgroup analysis should be interpreted with caution.

Randomized clinical trials are superior for establishing a causal association, but a scientific question such as ours is very difficult to test under such circumstances. Thus, a pooled analysis of cohort studies is a powerful approach to assess the relation between fatal MI and PA. The present study included data from several prospective population-based cohorts, which is a robust design for eliminating selection and recall biases.

Our pooled analysis provides strong support for the recommendations on weekly PA in healthy adults stated in the 2016 European Guidelines on cardiovascular disease prevention in clinical practice (10); especially as we used cut-off values for PA comparable to those used in the guidelines. We believe that our findings may be helpful to all health providers in their consultancy of healthy adults.

Study limitations

Our pooled analysis has several limitations. First, the observational study design warrants special consideration. We were unable to assess changes in PA levels and other cardiovascular risk factors over time in our analysis, which has introduced some inherent measurement error. The relationship between PA and cardiovascular risk factors is complex, multifaceted and time-dependent (42). Although reverse causation could contribute to the findings, stratified analysis by time from baseline assessment of PA to incident MI yielded similar results. Furthermore, potential bias due to other lifestyle measures not measured could not be

1 excluded. For instance, individuals who participate in moderate-to-high volume exercise may adhere to an
2 overall healthier lifestyle, i.e. a lower intake of salt and saturated fat, lower rates of smoking and less likely to
3 be overweight (43). We did find evidence of such 'healthy adherer effect' in our data (Appendix Table 1).
4 However, adjustments for major CV risk factors had little impact on risk estimates, indicating that residual
5 confounding was unlikely to explain our findings. Second, the number of cohorts included in our pooled
6 analysis was relatively small, a problem encountered in many pooled analyses. Of the ten included cohorts, just
7 three studies, i.e. the Copenhagen City Heart Study, the Cohort of Norway, and the Million Women Study,
8 accounted for almost 83% of patients and 77% of outcomes (Appendix Table 6). This, and the fact that nine out
9 of ten cohorts originated from Northern Europe, limits overall generalizability of our findings. The inclusion of
10 several smaller cohorts may have resulted in the moderate-to-high level of heterogeneity observed in our
11 subgroup analyses. Third, we could not exclude potential bias due to misclassification of PA levels,
12 cardiovascular risk factors, and fatal MI, as data were collected differently among individual cohort studies. We
13 observed significant heterogeneity between cohorts in all the above. Notably, the distribution of PA was right
14 skewed in the Dutch and UK cohorts, which is likely explained by the very detailed PA questionnaires used in
15 these cohorts (Appendix Table 5). Since only a smaller number of cohorts were included, ancillary analysis i.e.
16 using meta-regression to further explore heterogeneity was not meaningful. Fourth, prevalence of instant and
17 28-day fatal MI varied between cohorts, which may be due to selection of participants (44), recruitment period
18 and differences in registration practice of causes of death. Specifically, the out-of-hospital registration of cause-
19 of-death may have been associated with some inaccuracies. We addressed this issue by including only MI in
20 our main outcome measure as opposed to a broader definition of chronic CAD. This restrictive approach may
21 increase specificity while decreasing sensitivity (45). Finally, we find it highly unlikely that any inaccuracies in
22 the cause-of-death registration was associated with PA level.

1 In conclusion, our pooled analysis demonstrates that a moderate-to-high level of PA is associated with a lower
2 risk of instant and 28-day death in relation to a MI. These findings support the hypothesis that exercise may
3 reduce myocardial damage in the acute phase of a MI.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

1 Acknowledgements

2 The authors would like to thank the Million Women Study for providing data to this study.

3 Funding

4 This study was funded by the Danish Heart Foundation [grant no. 18-R124-A8318-22104]. The funding source
5 was not involved in study design; collection, analysis, and interpretation of data; writing of the report; or the
6 decision to submit the report for publication.

7 Conflict of interests

8 None declared.

9 Authors' contributions

10 KWH, NP, DP, VV, ML. PMV and EP participated in study design. KWH and EP obtained funding. KWH performed
11 data analysis and wrote the report. All authors interpreted the results, revised the report and approved the
12 final version.

13 Transparency declaration

14 The corresponding author had full access to all the data in the study and had final responsibility for the decision
15 to submit for publication. Aggregated data from each study cohort may be made available upon request.

16 Ethics approval

17 The study protocols of each participating cohort were approved by local ethics committees. This pooled
18 analysis of aggregated data did not require further ethical approval.

19

20

1 References

- 2 1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from
3 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of
4 Disease Study 2010. *Lancet*. 2012;380(9859):2095–128.
- 5 2. Moran AE, Forouzanfar MH, Roth G, Mensah G, Ezzati M, Murray CJL, et al. Temporal Trends in Ischemic
6 Heart Disease Mortality in 21 World Regions, 1980-2010: The Global Burden of Disease 2010 Study.
7 *Circulation*. 2014;129:1483–92.
- 8 3. Morris JN, Pollard R, Everitt MG, Chave SPW, Semmence AM. Vigorous Exercise in Leisure-Time:
9 Protection Against Coronary Heart Disease. *Lancet*. 1980;316(8206):1207–10.
- 10 4. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of Physical Activity on Life
11 Expectancy With Cardiovascular Disease. *Arch Intern Med*. 2005;165:2355–60.
- 12 5. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity
13 and risk of coronary heart disease: A meta-analysis. *Circulation*. 2011;124(7):789–95.
- 14 6. Löllgen H, Böckenhoff A, Knapp G. Physical activity and all-cause mortality: An updated meta-analysis
15 with different intensity categories. *Int J Sports Med*. 2009;30(3):213–24.
- 16 7. Lee I, Skerrett PJ. Physical activity and all-cause mortality : what is the dose-response relation ? *Med Sci*
17 *Sport Exerc*. 2001;33(6 Suppl):459–71.
- 18 8. Moore SC, Patel A V., Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, et al. Leisure Time
19 Physical Activity of Moderate to Vigorous Intensity and Mortality: A Large Pooled Cohort Analysis. *PLoS*
20 *Med*. 2012;9(11):e1001335.

- 1 9. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: Systematic review
2 and dose-response meta-analysis of cohort studies. *Int J Epidemiol.* 2011;40(5):1382–400.
- 3 10. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on
4 cardiovascular disease prevention in clinical practice. *Eur Heart J.* 2016;37(29):2315–81.
- 5 11. Thijssen DHJ, Redington A, George KP, Hopman MTE, Jones H. Association of Exercise Preconditioning
6 With Immediate Cardioprotection A Review What Is the Evidence for Exercise Preconditioning? *JAMA*
7 *Cardiol.* 2018;3(2):1–8.
- 8 12. Joyner MJ, Green DJ. Exercise protects the cardiovascular system: Effects beyond traditional risk factors.
9 *J Physiol.* 2009;587(23):5551–8.
- 10 13. Frasier CR, Moore RL, Brown DA. Exercise-induced cardiac preconditioning: how exercise protects your
11 achy-breaky heart. *J Appl Physiol.* 2011;111(3):905–15.
- 12 14. Williams RP, Manou-Stathopoulou V, Redwood SR, Marber MS. ‘Warm-up angina’: Harnessing the
13 benefits of exercise and myocardial ischaemia. *Postgrad Med J.* 2014;90(1069):648–56.
- 14 15. Michelsen MM, Støttrup NB, Schmidt MR, Løfgren B, Jensen R V., Tropak M, et al. Exercise-induced
15 cardioprotection is mediated by a bloodborne, transferable factor. *Basic Res Cardiol.* 2012;107(3):260.
- 16 16. Marongiu E, Crisafulli A. Cardioprotection Acquired Through Exercise: The Role of Ischemic
17 Preconditioning. *Curr Cardiol Rev.* 2014;10(4):336–48.
- 18 17. Kavazis AN. Exercise preconditioning of the myocardium. *Sport Med.* 2009;39(11):923–35.
- 19 18. Domenech R, Macho P, Schwarze H, Sánchez G. Exercise induces early and late myocardial
20 preconditioning in dogs. *Cardiovasc Res.* 2002;55(3):561–6.

- 1 19. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. *Nat Clin*
2 *Pract Cardiovasc Med*. 2004;1(2):96–102.
- 3 20. Pitsavos C, Kavouras SA, Panagiotakos DB, Arapi S, Anastasiou CA, Zombolos S, et al. Physical Activity
4 Status and Acute Coronary Syndromes Survival. *J Am Coll Cardiol*. 2008;51(21):2034–9.
- 5 21. Ejlersen H, Andersen ZJ, von Euler-Chelpin MC, Johansen PP, Schnohr P, Prescott E. Prognostic impact of
6 physical activity prior to myocardial infarction: Case fatality and subsequent risk of heart failure and
7 death. *Eur J Prev Cardiol*. 2017;24(10):1112–9.
- 8 22. Peytz NC, Jabbari R, Bojesen SE, Nordestgaard B, Schnohr P, Prescott E. Physical activity and risk of
9 instant and 28-day case-fatality in myocardial infarction. *PLoS One*. 2019;14(5):1–12.
- 10 23. Schnohr P, Marott JL, Jensen JS, Jensen GB. Intensity versus duration of cycling, impact on all-cause and
11 coronary heart disease mortality: The Copenhagen City Heart Study. *Eur J Prev Cardiol*. 2012;19(1):73–
12 80.
- 13 24. Chambless L, Keil U, Dobson A, Mähönen M, Kuulasmaa K, Rajakangas A-M, et al. Population Versus
14 Clinical View of Case Fatality From Acute Coronary Heart Disease: Results From the WHO MONICA
15 Project 1985-1990. *Circulation*. 1997;96(11):3849–59.
- 16 25. Gleser LJ, Olkin I. Stochastically dependent effect sizes. In: *The handbook of research synthesis and*
17 *meta-analysis*. 2nd editio. 2009. p. 357–76.
- 18 26. Nakagawa S, Santos ESA. Methodological issues and advances in biological meta-analysis. *Evol Ecol*.
19 2012;26(5):1253–74.
- 20 27. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw*. 2010;36(3):1–48.

- 1 28. Team RDC. R: A language and environment for statistical computing. [Internet]. Vol. 1, R Foundation for
2 Statistical Computing. Vienna, Austria: (R Core Team) R Foundation for Statistical Computing; 2013.
- 3 29. Rücker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise
4 meta-analysis. *Res Synth Methods*. 2017;8(4):392–403.
- 5 30. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-hansen A. Nonfasting Triglycerides and Risk of
6 Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. *JAMA*. 2007;298(3):299–
7 308.
- 8 31. Osler M, Linneberg A, Glümer C, Jørgensen T. The cohorts at the research centre for prevention and
9 health, formerly “the glostrup population studies.” *Int J Epidemiol*. 2011;40(3):602–10.
- 10 32. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of
11 Loss-of-Function Mutations in the ABCA1 Gene With High-Density. *JAMA*. 2008;299(21):2524–32.
- 12 33. Beulens JWJ, Monninkhof EM, Monique Verschuren WM, van der Schouw YT, Smit J, Ocke MC, et al.
13 Cohort profile: The EPIC-NL study. *Int J Epidemiol*. 2010;39(5):1170–8.
- 14 34. Franco OH, Nijsten TEC, van Duijn CM, Stricker BH, Murad SD, Vernooij MW, et al. The Rotterdam Study:
15 2018 update on objectives, design and main results. *Eur J Epidemiol*. 2017;32(9):807–50.
- 16 35. Næss Ø, Sjøgaard AJ, Arnesen E, Beckstrøm AC, Bjertness E, Engeland A, et al. Cohort Profile: Cohort of
17 Norway (CONOR). *Int J Epidemiol*. 2007;37(3):481–5.
- 18 36. Moreau M, Valente F, Mak R, Pelfrene E, De Smet P, De Backer G, et al. Occupational stress and
19 incidence of sick leave in the Belgian workforce: The Belstress study. *J Epidemiol Community Health*.
20 2004;58(6):507–16.

- 1 37. Kouviri M, Panagiotakos DB, Yannakoulia M, Georgousopoulou E, Critselis E, Chrysohoou C, et al.
2 Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular
3 disease incidence: The ATTICA cohort study. *Metabolism*. 2019;93:18–24.
- 4 38. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource
5 for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med*.
6 2015;12(3):e1001779.
- 7 39. Abete P, Ferrara N, Cacciatore F, Sagnelli E, Manzi M, Carnovale V, et al. High level of physical activity
8 preserves the cardioprotective effect of preinfarction angina in elderly patients. *J Am Coll Cardiol*.
9 2002;38(5):1357–65.
- 10 40. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The Incidence of Primary Cardiac Arrest during Vigorous
11 Exercise. *N Engl J Med*. 1984;311:874–7.
- 12 41. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of Acute
13 Myocardial Infarction by Heavy Physical Exertion: Protection Against Triggering by Regular Exertion. *N*
14 *Engl J Med*. 1993;329(23):1677–83.
- 15 42. 2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory
16 Committee Scientific Report. Washington DC; 2018.
- 17 43. Laursen AH, Kristiansen OP, Marott JL, Schnohr P, Prescott E. Intensity versus duration of physical
18 activity: Implications for the metabolic syndrome. A prospective cohort study. *BMJ Open*. 2012;2(5):1–8.
- 19 44. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic
20 and Health-Related Characteristics of UK Biobank Participants with Those of the General Population. *Am*
21 *J Epidemiol*. 2017;186(9):1026–34.

- 1 45. Kjølner E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al. Agreement between public
2 register and adjudication in a cardiovascular randomized trial. Am Heart J. 2014;168(2):197-204.

3

Tables

Table 1 Clinical characteristics at baseline assessment for 28 140 patients with subsequent incident MI, by individual cohort										
	ATTICA	BELSTRESS	CCHS	CGPS	CONOR	CRPH	MORGEN- project	MWS	Rotterdam study	UK Biobank
No. of patients	177	39	1664	1401	9120	778	337	10 451	384	3789
Age, years	59.1 (13.3)	51.2 (3.7)	64.8 (9.2)	70.1 (11.6)	71.2 (12.6)	51.3 (10.1)	58.1 (8.6)	70.3 (6.6)	70.5 (7.7)	63.0 (6.9)
Male sex, %	70	100	59	63	69	70	69	0	45	73
Diabetes mellitus, %	25	10	5	12	30	7	5	8	17	10
Hypertension, %	44	46	56	27	62	30	40	40	27	34
Family history of CVD, %	32	NA	40	35	53	NA	38	53	21	NA
Active smoking, %	39	72	71	28	36	58	53	58	22	20
BMI, kg/m²	27.6 (3.7)	28.1 (3.6)	25.9 (4.0)	27.3 (4.2)	27.0 (3.9)	26.6 (4.1)	27.0 (4.2)	26.5 (4.8)	27.1 (3.9)	28.5 (4.6)
Cholesterol, mmol/L	5.5 (1.1)	6.4 (1.1)	6.5 (1.2)	5.9 (1.2)	6.4 (1.2)	6.5 (1.3)	5.8 (1.0)	NA	5.9 (0.9)	5.9 (1.2)
SBP, mmHg	130 (17)	139 (13)	142 (22)	150 (21)	148 (22)	133 (19)	131 (18)	NA	149 (20)	149 (21)
DBP, mmHg	81 (11)	89.3 (13)	85 (12)	86 (12)	83 (12)	NA	82 (11)	NA	78 (11)	85 (11)
Level of physical activity, %										
Sedentary	61.6	28.2	20.8	7.9	42.7	26.7	2.1	2.4	1.0	14.7
Low	11.9	48.7	54.0	50.5	25.6	54.5	4.2	5.8	3.1	16.4
Moderate	9.0	23.1	23.9	36.4	23.3	18.1	9.5	15.2	6.8	20.6

High	17.5	0.0	1.3	5.2	8.4	0.7	84.2	76.6	89.1	48.3
28-day fatal MI, no. (%)	NA	NA	650 (39)	95 (11)	1917 (21)	95 (12)	53 (16)	1509 (14)	87 (23)	421 (11)
Instant	69 (39)	17 (44)	425 (26)	66 (5)	1160 (13)	21 (3)	46 (14)	1220 (12)	27 (7)	21 (1)
<p>BELSTRESS, Belgian Job Stress Study. CCHS, Copenhagen City Heart Study. CGPS, Copenhagen General Population Study. CONOR, Cohort of Norway. CRPH, Cohort of the Research for Prevention and Health. CVD, cardiovascular disease. DBP, diastolic blood pressure. MI, myocardial infarction. MORGEN-project, Monitoring Risicofactoren en Gezondheid in Nederland. MWS, the Million Women Study. SBP, systolic blood pressure. UK Biobank, United Kingdom Biobank.</p> <p>No. are mean (standard deviation) unless otherwise is specified.</p>										

	Number of cohorts	Number of patients (events)	Level of physical activity				I ² , %
			Sedentary	Low	Moderate	High	
Instant fatal MI							
Time from baseline to MI							
< 5 years	5	6110 (815)	1	0.72 (0.54-0.96)	0.70 (0.52-0.94)	0.60 (0.43-0.85)	19.2
≥ 5 years	6	16 910 (2188)	1	0.68 (0.47-0.99)	0.60 (0.41-0.87)	0.52 (0.36-0.76)	73.1
Age at baseline							
< 65 years	6	6336 (460)	1	0.86 (0.63-1.16)	0.82 (0.61-1.01)	0.71 (0.51-1.00)	<0.1
≥ 65 years	5	17 169 (2527)	1	0.63 (0.45-0.89)	0.57 (0.40-0.81)	0.50 (0.35-0.71)	75.2
Sex							
Males	6	9060 (1180)	1	0.51 (0.19-1.32)	0.47 (0.18-1.24)	0.29 (0.11-0.76)	94.4
Females	6	14 690 (1823)	1	0.75 (0.57-0.98)	0.65 (0.49-0.86)	0.59 (0.45-0.78)	40.0
Body-mass index							
< 30 kg/m ²	7	18 666 (2270)	1	0.71 (0.56-0.91)	0.62 (0.49-0.80)	0.55 (0.43-0.72)	40.3
≥ 30 kg/m ²	5	4224 (596)	1	0.79 (0.53-1.17)	0.74 (0.49-1.10)	0.70 (0.46-1.06)	36.5
Diabetes mellitus							
Yes	5	3824 (591)	1	0.73 (0.51-1.06)	0.71 (0.48-1.05)	0.58 (0.38-0.88)	17.1
No	5	18 830 (2357)	1	0.65 (0.41-1.02)	0.57 (0.35-0.92)	0.62 (0.36-1.08)	27.6
Arterial hypertension							
Yes	6	11 462 (1735)	1	0.81 (0.66-1.00)	0.70 (0.56-0.87)	0.65 (0.51-0.83)	21.2
No	5	11 552 (1232)	1	0.65 (0.49-0.87)	0.67 (0.49-0.90)	0.56 (0.41-0.75)	43.5
28-day fatal MI							
Time from baseline to MI							
< 5 years	6	6476 (394)	1	0.78 (0.58-1.05)	0.69 (0.49-0.96)	0.62 (0.41-0.94)	<0.1
≥ 5 years	6	14 858 (1417)	1	0.79 (0.67-0.93)	0.65 (0.54-0.78)	0.70 (0.58-0.86)	<0.1
Age at baseline							
< 65 years	5	6771 (281)	1	0.87 (0.59-1.28)	0.81 (0.53-1.23)	0.78 (0.50-1.23)	17.0
≥ 65 years	5	14 107 (1515)	1	0.76 (0.65-0.89)	0.60 (0.50-0.71)	0.63 (0.52-0.76)	<0.1
Sex							
Males	5	9336 (1014)	1	0.72 (0.60-0.87)	0.66 (0.54-0.80)	0.71 (0.57-0.89)	<0.1

Females	6	12 020 (797)	1	0.86 (0.69-1.07)	0.54 (0.41-0.72)	0.59 (0.44-0.80)	<0.1
Body-mass index							
< 30 kg/m ²	6	16 504 (1402)	1	0.79 (0.68-0.93)	0.59 (0.49-0.70)	0.59 (0.48-0.73)	<0.1
≥ 30 kg/m ²	6	4242 (377)	1	0.74 (0.51-1.08)	0.85 (0.58-1.26)	1.00 (0.68-1.47)	9.2
Diabetes mellitus							
Yes	3	2104 (293)	1	0.65 (0.49-0.86)	0.54 (0.38-0.79)	0.60 (0.31-1.16)	<0.1
No	3	6671 (747)	1	0.81 (0.53-1.25)	0.62 (0.40-0.97)	0.45 (0.27-0.77)	68.9
Arterial hypertension							
Yes	5	9077 (1034)	1	0.85 (0.70-1.02)	0.54 (0.44-0.67)	0.56 (0.45-0.71)	3.7
No	5	11 063 (707)	1	0.72 (0.57-0.90)	0.56 (0.44-0.73)	0.70 (0.54-0.91)	<0.1
CI, confidence interval. All odds ratios were adjusted for age and sex prior to pooled analysis. No test for interaction between level of PA and subgroup reached a two-sided statistical significance level of 0.10.							

Figure Legends

Figure 1 Flow diagram displaying the cohort selection process

Figure 2 Forest plot for instant fatal myocardial infarction, by exposure contrast using sedentary as reference

The fully adjusted RE model was adjusted for age, sex, diabetes mellitus, arterial hypertension, family history of CVD, smoking, BMI, total blood cholesterol level, alcohol consumption and socioeconomic status.

CCHS, Copenhagen City Heart Study. CGPS, Copenhagen General Population Study. CONOR, Cohort of Norway. CRPH, Cohort of the Research for Prevention and Health. MORGEN-project, Monitoring Risicofactoren en Gezondheid in Nederland. PA, physical activity. RE, random-effects. UK Biobank, United Kingdom Biobank.

Figure 3 Forest plot for 28-day fatal myocardial infarction, by exposure contrast using sedentary as reference

The fully adjusted RE model was adjusted for age, sex, diabetes mellitus, arterial hypertension, family history of CVD, smoking, BMI, total blood cholesterol level, alcohol consumption and socioeconomic status.

CCHS, Copenhagen City Heart Study. CGPS, Copenhagen General Population Study. CONOR, Cohort of Norway. CRPH, Cohort of the Research for Prevention and Health. PA, physical activity. RE, random-effects. UK Biobank, United Kingdom Biobank.